CN103933060B - 红芪多糖在制备预防或治疗骨质疏松药物或保健品中的应用 - Google Patents
红芪多糖在制备预防或治疗骨质疏松药物或保健品中的应用 Download PDFInfo
- Publication number
- CN103933060B CN103933060B CN201410171055.9A CN201410171055A CN103933060B CN 103933060 B CN103933060 B CN 103933060B CN 201410171055 A CN201410171055 A CN 201410171055A CN 103933060 B CN103933060 B CN 103933060B
- Authority
- CN
- China
- Prior art keywords
- hedysamn polysaccharide
- hedysamn
- hps3
- polysaccharide
- health product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 66
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 66
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 66
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 33
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 230000002265 prevention Effects 0.000 title claims abstract description 12
- 230000036541 health Effects 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 7
- 230000011164 ossification Effects 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 230000001009 osteoporotic effect Effects 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 4
- 238000013459 approach Methods 0.000 claims description 3
- -1 patch Substances 0.000 claims description 3
- 239000003405 delayed action preparation Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000700159 Rattus Species 0.000 abstract description 37
- 230000000694 effects Effects 0.000 abstract description 26
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 18
- 239000011575 calcium Substances 0.000 abstract description 18
- 229910052791 calcium Inorganic materials 0.000 abstract description 18
- 102100028902 Hermansky-Pudlak syndrome 1 protein Human genes 0.000 abstract description 17
- 102100028716 Hermansky-Pudlak syndrome 3 protein Human genes 0.000 abstract description 17
- 101000985492 Homo sapiens Hermansky-Pudlak syndrome 3 protein Proteins 0.000 abstract description 17
- 210000000988 bone and bone Anatomy 0.000 abstract description 16
- 230000037182 bone density Effects 0.000 abstract description 14
- 102100028715 Hermansky-Pudlak syndrome 4 protein Human genes 0.000 abstract description 12
- 101000838926 Homo sapiens Hermansky-Pudlak syndrome 1 protein Proteins 0.000 abstract description 12
- 101000985501 Homo sapiens Hermansky-Pudlak syndrome 4 protein Proteins 0.000 abstract description 12
- 238000012360 testing method Methods 0.000 abstract description 11
- 230000009471 action Effects 0.000 abstract description 3
- 230000001629 suppression Effects 0.000 abstract description 3
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 210000000963 osteoblast Anatomy 0.000 description 17
- 210000000689 upper leg Anatomy 0.000 description 17
- 102000004264 Osteopontin Human genes 0.000 description 9
- 108010081689 Osteopontin Proteins 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 230000004072 osteoblast differentiation Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 101000985500 Staphylococcus saprophyticus subsp. saprophyticus (strain ATCC 15305 / DSM 20229 / NCIMB 8711 / NCTC 7292 / S-41) 3-hexulose-6-phosphate synthase 3 Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241001269238 Data Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000266851 Hedysarum polybotrys Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 102000002624 Sp7 Transcription Factor Human genes 0.000 description 2
- 108010043267 Sp7 Transcription Factor Proteins 0.000 description 2
- 101000985497 Staphylococcus saprophyticus subsp. saprophyticus (strain ATCC 15305 / DSM 20229 / NCIMB 8711 / NCTC 7292 / S-41) 3-hexulose-6-phosphate synthase 1 Proteins 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000001226 reprecipitation Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241000214032 Hedysarum Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 238000003321 atomic absorption spectrophotometry Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 238000011633 osteoporosis animal model Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410171055.9A CN103933060B (zh) | 2014-04-25 | 2014-04-25 | 红芪多糖在制备预防或治疗骨质疏松药物或保健品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410171055.9A CN103933060B (zh) | 2014-04-25 | 2014-04-25 | 红芪多糖在制备预防或治疗骨质疏松药物或保健品中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103933060A CN103933060A (zh) | 2014-07-23 |
CN103933060B true CN103933060B (zh) | 2016-08-17 |
Family
ID=51181118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410171055.9A Active CN103933060B (zh) | 2014-04-25 | 2014-04-25 | 红芪多糖在制备预防或治疗骨质疏松药物或保健品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103933060B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106830350A (zh) * | 2016-12-31 | 2017-06-13 | 新昌县派特普科技有限公司 | 水产养殖的复合水质改良剂及其制备方法 |
CN108892733B (zh) * | 2018-05-25 | 2021-04-30 | 兰州大学 | 一种红芪多糖修饰方法及修饰的红芪多糖的应用 |
CN115364276B (zh) * | 2022-08-19 | 2023-06-09 | 兰州大学第二医院 | 一种含红芪多糖的复合增强型磷酸钙骨水泥及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103059152A (zh) * | 2011-12-06 | 2013-04-24 | 封士兰 | 红芪多糖3的分离物及其用途 |
-
2014
- 2014-04-25 CN CN201410171055.9A patent/CN103933060B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103059152A (zh) * | 2011-12-06 | 2013-04-24 | 封士兰 | 红芪多糖3的分离物及其用途 |
Non-Patent Citations (2)
Title |
---|
苏开鑫等.《红芪水提液防治大鼠类固醇性骨质疏松的实验研究》.《实用中西医结合临床》.2005,第5卷(第4期),4-5页. * |
赵良功等.《4种红芪多糖对实验性糖尿病小鼠血糖的影响》.《Journal of Chinese Medicinal Materials》.2009,第32卷(第10期),第1590-1592页. * |
Also Published As
Publication number | Publication date |
---|---|
CN103933060A (zh) | 2014-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103251671B (zh) | 一种增加骨密度的含中药的组合物及其制备方法 | |
CN103933060B (zh) | 红芪多糖在制备预防或治疗骨质疏松药物或保健品中的应用 | |
Chen et al. | Synergy effects of Asperosaponin VI and bioactive factor BMP-2 on osteogenesis and anti-osteoclastogenesis | |
CN102526326B (zh) | 用于治疗绝经后骨质疏松症的中药及其制备方法 | |
CN100479849C (zh) | 一种治疗骨质疏松症的药物及其生产方法 | |
CN101455704B (zh) | 一种预防和治疗骨质疏松的中药组合物及其制备方法 | |
CN102266415A (zh) | 一种复方中药在防治骨质疏松疾病中的应用 | |
CN104257762B (zh) | 一种药物组合物及其预防和治疗骨质疏松的用途 | |
CN107744571B (zh) | 一种改善血管内皮功能障碍的药物组合物及其制备方法和用途 | |
CN105381039A (zh) | 一种治疗原发性骨质疏松症的中药组合物及其制备方法 | |
CN102526005A (zh) | 甲磺酸去铁胺在制备治疗绝经后骨质疏松疾病药物中的用途 | |
CN110151747A (zh) | Ferrostatin-1在治疗骨质疏松疾病中的用途 | |
CN103919908B (zh) | 一种预防和治疗废用性骨质疏松的药物及其制备方法 | |
CN111870689A (zh) | 一种纳豆激酶在治疗骨质疏松药物中的应用 | |
Leung et al. | Developing an effective food supplement for the prevention of osteoporosis | |
CN110433226A (zh) | 一种用于治疗痛风性关节炎或高尿酸血症的中药组合物和制剂及其制备方法和应用 | |
US11517602B2 (en) | Traditional Chinese medicine composition for improving bone health and preparation and uses thereof | |
CN101352480B (zh) | 一种治疗骨质疏松症的中药组合物及其制备方法 | |
CN100459985C (zh) | 当归油在制备治疗更年期综合征和骨质疏松的药物中的应用 | |
CN109125413A (zh) | 一种具有补肾壮阳作用的中药组合物制剂及其制备方法 | |
CN111991405B (zh) | 莪术二酮联合白果新酸在制备促进骨形成药物中的应用 | |
CN116212007B (zh) | 一种治疗中期骨折的接骨柔筋中药组合物及其制备方法 | |
WO2022247640A1 (zh) | 一种预防或治疗原发性骨质疏松症药物组合物及其制备方法 | |
CN107137587A (zh) | 一种利用动物肾脏的补肾药及其制备方法 | |
CN102366431A (zh) | 人参花在制备防治骨质疏松症药物制剂的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190423 Address after: 748100 North of Chang'an Road, Longxi County, Dingxi City, Gansu Province Patentee after: GANSU ZHONGTIAN PHARMACEUTICAL Co.,Ltd. Address before: 730000 No. 222 Tianshui South Road, Chengguan District, Lanzhou, Gansu Patentee before: Lanzhou University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201116 Address after: 748100 North Road, Changan Road, Longxi County, Gansu, Dingxi Patentee after: GANSU ZHONGTIAN JINDAN PHARMACEUTICAL Co.,Ltd. Address before: 748100 North Road, Changan Road, Longxi County, Gansu, Dingxi Patentee before: GANSU ZHONGTIAN PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address |
Address after: 748100 North of Chang'an Road, Longxi County, Dingxi City, Gansu Province Patentee after: Gansu Zhijiao Pharmaceutical Co.,Ltd. Country or region after: China Address before: 748100 North of Chang'an Road, Longxi County, Dingxi City, Gansu Province Patentee before: GANSU ZHONGTIAN JINDAN PHARMACEUTICAL Co.,Ltd. Country or region before: China |